A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial.
Naoki IzawaToshiki MasuishiNaoki TakahashiHirokazu ShojiYoshiyuki YamamotoToshihiko MatsumotoKeiji SugiyamaTakeshi KajiwaraKentaro KawakamiNaoki AomatsuChihiro KondohHisato KawakamiNaoki TakegawaTaito EsakiMototsugu ShimokawaKazuto NishioYukiya NaritaHiroki HaraYu SunakawaNarikazu BokuToshikazu MoriwakiTakako Eguchi NakajimaKei MuroPublished in: Targeted oncology (2023)
FTD/TPI plus cetuximab rechallenge did not demonstrate clinically meaningful efficacy in all mCRC patients, but might be beneficial for the molecularly selected population.
Keyphrases
- wild type
- metastatic colorectal cancer
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- small cell lung cancer
- prognostic factors
- peritoneal dialysis
- study protocol
- tyrosine kinase
- phase iii
- squamous cell carcinoma
- radiation therapy
- randomized controlled trial
- patient reported outcomes
- phase ii
- rectal cancer